相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications
Alfonso Zaccaria et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Flexible statistical models provided new insights into the role of quantitative prognostic factors for mortality in gastric cancer
Christine Binquet et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany
M. Rohrbacher et al.
LEUKEMIA (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level
Hermann Brenner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Chronic myeloid leukaemia
Ruediger Hehlmann et al.
LANCET (2007)
An overall strategy based on regression models to estimate relative survival and model the effects of prognostic factors in cancer survival studies
L. Remontet et al.
STATISTICS IN MEDICINE (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia:: historical comparison between two phase 3 trials
Lydia Roy et al.
BLOOD (2006)
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase - Comparison with historic data
HM Kantarjian et al.
CANCER (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
